Interacciones de Palonosetrón

Serotonin syndrome : reported with 5-HT 3 receptor antagonists alone, but particularly with concomitant use of serotonergic drugs. (etiqueta de Palonosetrón, Advertencias y precauciones)

Serotonin syndrome : reported with 5-HT 3 receptor antagonists alone, but particularly with concomitant use of serotonergic drugs. (etiqueta de Palonosetrón, Advertencias y precauciones)

Serotonin syndrome : reported with 5-HT 3 receptor antagonists alone, but particularly with concomitant use of serotonergic drugs. (etiqueta de Palonosetrón, Advertencias y precauciones)

Serotonin Syndrome: Increased risk when co-administered with serotonergic agents (e.g., SSRIs, SNRIs, triptans), but also during overdosage situations. (etiqueta de Anfetamina, Advertencias y precauciones)

Serotonin Syndrome: Increased risk when coadministered with serotonergic agents (e.g., selective serotonin reuptake inhibitors (SSRIs), serotonin norepinephrine reuptake inhibitors (SNRIs), triptans), but also during overdosage situations. (etiqueta de Anfetamina y dexanfetamina, Advertencias y precauciones)

Patients should be monitored for the emergence of serotonin syndrome, especially with concomitant use of POSFREA and other serotonergic drugs. (etiqueta de Palonosetrón, Advertencias y precauciones)

• Serotonergic Drugs: Concomitant use may result in serotonin syndrome. (etiqueta de Belladona y opio, Interacciones medicamentosas)

Patients should be monitored for the emergence of serotonin syndrome, especially with concomitant use of POSFREA and other serotonergic drugs. (etiqueta de Palonosetrón, Advertencias y precauciones)

Serotonergic Drugs : Concomitant use may result in serotonin syndrome. (etiqueta de Buprenorfina, Interacciones medicamentosas)

Serotonergic Drugs: Concomitant use may result in serotonin syndrome. (etiqueta de Buprenorfina y naloxona, Interacciones medicamentosas)

Patients should be monitored for the emergence of serotonin syndrome, especially with concomitant use of POSFREA and other serotonergic drugs. (etiqueta de Palonosetrón, Advertencias y precauciones)

Intervention: Avoid concomitant use Serotonergic Drugs : Concomitant use may result in serotonin syndrome. (etiqueta de Butalbital, ácido acetilsalicílico, cafeína y codeína, Interacciones medicamentosas)

• Serotonergic Drugs: Concomitant use may result in serotonin syndrome. (etiqueta de Butalbital, paracetamol, cafeína y codeína, Interacciones medicamentosas)

…medical attention if they ‎experience symptoms of hyperalgesia, including worsening pain, increased ‎sensitivity to pain, or new pain [see WARNINGS ; ADVERSE REACTIONS ].‎ Serotonin Syndrome Inform patients that butorphanol tartrate could cause a rare but potentially life-threatening condition resulting from concomitant administration of serotonergic drugs. (etiqueta de Butorfanol, Precauciones)

Patients should be monitored for the emergence of serotonin syndrome, especially with concomitant use of POSFREA and other serotonergic drugs. (etiqueta de Palonosetrón, Advertencias y precauciones)

Serotonin syndrome : reported with 5-HT 3 receptor antagonists alone, but particularly with concomitant use of serotonergic drugs. (etiqueta de Palonosetrón, Advertencias y precauciones)

Serotonin syndrome : reported with 5-HT 3 receptor antagonists alone, but particularly with concomitant use of serotonergic drugs. (etiqueta de Palonosetrón, Advertencias y precauciones)

• Serotonergic Drugs: Concomitant use may result in serotonin syndrome. (etiqueta de Codeína, Interacciones medicamentosas)

Serotonin syndrome : reported with 5-HT 3 receptor antagonists alone, but particularly with concomitant use of serotonergic drugs. (etiqueta de Palonosetrón, Advertencias y precauciones)

Serotonin syndrome : reported with 5-HT 3 receptor antagonists alone, but particularly with concomitant use of serotonergic drugs. (etiqueta de Palonosetrón, Advertencias y precauciones)

Serotonin Syndrome Serotonin syndrome, a potentially life-threatening reaction, may occur when amphetamines are used in combination with other drugs that affect the serotonergic neurotransmitter systems such as monoamine oxidase inhibitors (MAOIs), selective serotonin reuptake inhibitors (SSRIs), serotonin norepinephrine reuptake inhibitors (SNRIs), triptans,… (etiqueta de Dexanfetamina, Advertencias)

Patients should be monitored for the emergence of serotonin syndrome, especially with concomitant use of POSFREA and other serotonergic drugs. (etiqueta de Palonosetrón, Advertencias y precauciones)

Patients should be monitored for the emergence of serotonin syndrome, especially with concomitant use of POSFREA and other serotonergic drugs. (etiqueta de Palonosetrón, Advertencias y precauciones)

Patients should be monitored for the emergence of serotonin syndrome, especially with concomitant use of POSFREA and other serotonergic drugs. (etiqueta de Palonosetrón, Advertencias y precauciones)

Serotonin syndrome : reported with 5-HT 3 receptor antagonists alone, but particularly with concomitant use of serotonergic drugs. (etiqueta de Palonosetrón, Advertencias y precauciones)

Serotonin syndrome : reported with 5-HT 3 receptor antagonists alone, but particularly with concomitant use of serotonergic drugs. (etiqueta de Palonosetrón, Advertencias y precauciones)

Serotonin syndrome : reported with 5-HT 3 receptor antagonists alone, but particularly with concomitant use of serotonergic drugs. (etiqueta de Palonosetrón, Advertencias y precauciones)

Serotonin syndrome : reported with 5-HT 3 receptor antagonists alone, but particularly with concomitant use of serotonergic drugs. (etiqueta de Palonosetrón, Advertencias y precauciones)

Patients should be monitored for the emergence of serotonin syndrome, especially with concomitant use of POSFREA and other serotonergic drugs. (etiqueta de Palonosetrón, Advertencias y precauciones)

• Serotonin Syndrome : Potentially life-threatening condition could result from concomitant serotonergic drug administration. (etiqueta de Fentanilo, Advertencias y precauciones)

Patients should be monitored for the emergence of serotonin syndrome, especially with concomitant use of POSFREA and other serotonergic drugs. (etiqueta de Palonosetrón, Advertencias y precauciones)

Serotonin syndrome : reported with 5-HT 3 receptor antagonists alone, but particularly with concomitant use of serotonergic drugs. (etiqueta de Palonosetrón, Advertencias y precauciones)

Serotonin syndrome : reported with 5-HT 3 receptor antagonists alone, but particularly with concomitant use of serotonergic drugs. (etiqueta de Palonosetrón, Advertencias y precauciones)

Serotonin syndrome : reported with 5-HT 3 receptor antagonists alone, but particularly with concomitant use of serotonergic drugs. (etiqueta de Palonosetrón, Advertencias y precauciones)

Patients should be monitored for the emergence of serotonin syndrome, especially with concomitant use of POSFREA and other serotonergic drugs. (etiqueta de Palonosetrón, Advertencias y precauciones)

Example: lactulose Serotonergic Drugs : Concomitant use may result in serotonin syndrome. (etiqueta de Hidrocodona, Interacciones medicamentosas)

S er otonin Syndrome Inform patients that opioids could cause a rare but potentially life-threatening condition resulting from concomitant administration of serotonergic drugs. (etiqueta de Hidrocodona e ibuprofeno, Precauciones)

Serotonergic drugs : Concomitant use may result in serotonin syndrome. (etiqueta de Hidrocodona y clorfenamina, Interacciones medicamentosas)

Serotonergic Drugs : Concomitant use may result in serotonin syndrome. (etiqueta de Hidrocodona y homatropina, Interacciones medicamentosas)

Serotonin Syndrome Inform patients that hydrocodone bitartrate and acetaminophen tablets could cause a rare but potentially life-threatening condition resulting from concomitant administration of serotonergic drugs. (etiqueta de Hidrocodona y paracetamol, Precauciones)

• Serotonergic Drugs : Concomitant use may result in serotonin syndrome. (etiqueta de Hidromorfona, Interacciones medicamentosas)

Combinar la hierba de San Juan (hipérico) con antidepresivos y otros fármacos serotoninérgicos aumenta el riesgo de síndrome serotoninérgico. (NCCIH, St. John's Wort)

Serotonin syndrome : reported with 5-HT 3 receptor antagonists alone, but particularly with concomitant use of serotonergic drugs. (etiqueta de Palonosetrón, Advertencias y precauciones)

Serotonin syndrome : reported with 5-HT 3 receptor antagonists alone, but particularly with concomitant use of serotonergic drugs. (etiqueta de Palonosetrón, Advertencias y precauciones)

Serotonin Syndrome Inform patients that opioids could cause a rare but potentially life-threatening condition resulting from concomitant administration of serotonergic drugs. (etiqueta de Levorfanol, Precauciones)

Patients should be monitored for the emergence of serotonin syndrome, especially with concomitant use of POSFREA and other serotonergic drugs. (etiqueta de Palonosetrón, Advertencias y precauciones)

Serotonin Syndrome: Increased risk when co-administered with serotonergic agents (e.g., SSRIs, SNRIs, triptans), but also during overdosage situations. (etiqueta de Lisdexanfetamina, Advertencias y precauciones)

Patients should be monitored for the emergence of serotonin syndrome, especially with concomitant use of POSFREA and other serotonergic drugs. (etiqueta de Palonosetrón, Advertencias y precauciones)

Serotonin Syndrome : Potentially life-threatening condition could result from concomitant serotonergic drug administration. (etiqueta de Metadona, Advertencias y precauciones)

Serotonin Syndrome: Increased risk when coadministered with serotonergic agents (e.g., SSRIs, SNRIs, triptans), but also during overdosage situations. (etiqueta de Metanfetamina, Advertencias y precauciones)

Serotonin syndrome has resulted from concomitant use of metaxalone (within the recommended dosage range) and other serotonergic drugs [see Warnings and Precautions (5.1) ]. (etiqueta de Metaxalona, Interacciones medicamentosas)

Serotonin syndrome : reported with 5-HT 3 receptor antagonists alone, but particularly with concomitant use of serotonergic drugs. (etiqueta de Palonosetrón, Advertencias y precauciones)

Patients should be monitored for the emergence of serotonin syndrome, especially with concomitant use of POSFREA and other serotonergic drugs. (etiqueta de Palonosetrón, Advertencias y precauciones)

• Serotonergic Drugs: Concomitant use may result in serotonin syndrome. (etiqueta de Morfina, Interacciones medicamentosas)

Serotonin syndrome : reported with 5-HT 3 receptor antagonists alone, but particularly with concomitant use of serotonergic drugs. (etiqueta de Palonosetrón, Advertencias y precauciones)

Patients should be monitored for the emergence of serotonin syndrome, especially with concomitant use of POSFREA and other serotonergic drugs. (etiqueta de Palonosetrón, Advertencias y precauciones)

Serotonin syndrome : reported with 5-HT 3 receptor antagonists alone, but particularly with concomitant use of serotonergic drugs. (etiqueta de Palonosetrón, Advertencias y precauciones)

Serotonin syndrome : reported with 5-HT 3 receptor antagonists alone, but particularly with concomitant use of serotonergic drugs. (etiqueta de Palonosetrón, Advertencias y precauciones)

Serotonergic Drugs : Concomitant use may result in serotonin syndrome. (etiqueta de Oliceridina, Interacciones medicamentosas)

Patients should be monitored for the emergence of serotonin syndrome, especially with concomitant use of POSFREA and other serotonergic drugs. (etiqueta de Palonosetrón, Advertencias y precauciones)

Serotonergic Drug s: Concomitant use may result in serotonin syndrome. (etiqueta de Oxicodona, Interacciones medicamentosas)

Serotonergic Drugs : Concomitant use may result in serotonin syndrome. (etiqueta de Oximorfona, Interacciones medicamentosas)

Serotonin Syndrome Inform patients that opioids could cause a rare but potentially life-threatening condition resulting from concomitant administration of serotonergic drugs. (etiqueta de Paracetamol y codeína, Precauciones)

Serotonin syndrome : reported with 5-HT 3 receptor antagonists alone, but particularly with concomitant use of serotonergic drugs. (etiqueta de Palonosetrón, Advertencias y precauciones)

Serotonin Syndrome Inform patients that opioids could cause a rare but potentially life-threatening condition resulting from concomitant administration of serotonergic drugs. (etiqueta de Pentazocina y naloxona, Precauciones)

Patients should be monitored for the emergence of serotonin syndrome, especially with concomitant use of POSFREA and other serotonergic drugs. (etiqueta de Palonosetrón, Advertencias y precauciones)

Serotonergic Drugs : Concomitant use may result in serotonin syndrome. (etiqueta de Prometazina y codeína, Interacciones medicamentosas)

Patients should be monitored for the emergence of serotonin syndrome, especially with concomitant use of POSFREA and other serotonergic drugs. (etiqueta de Palonosetrón, Advertencias y precauciones)

Serotonin syndrome : reported with 5-HT 3 receptor antagonists alone, but particularly with concomitant use of serotonergic drugs. (etiqueta de Palonosetrón, Advertencias y precauciones)

Patients should be monitored for the emergence of serotonin syndrome, especially with concomitant use of POSFREA and other serotonergic drugs. (etiqueta de Palonosetrón, Advertencias y precauciones)

Patients should be monitored for the emergence of serotonin syndrome, especially with concomitant use of POSFREA and other serotonergic drugs. (etiqueta de Palonosetrón, Advertencias y precauciones)

• Serotonin Syndrome : Potentially life-threatening condition could result from concomitant serotonergic drug administration. (etiqueta de Remifentanilo, Advertencias y precauciones)

Serotonin syndrome : reported with 5-HT 3 receptor antagonists alone, but particularly with concomitant use of serotonergic drugs. (etiqueta de Palonosetrón, Advertencias y precauciones)

Patients should be monitored for the emergence of serotonin syndrome, especially with concomitant use of POSFREA and other serotonergic drugs. (etiqueta de Palonosetrón, Advertencias y precauciones)

Serotonin syndrome : reported with 5-HT 3 receptor antagonists alone, but particularly with concomitant use of serotonergic drugs. (etiqueta de Palonosetrón, Advertencias y precauciones)

Serotonin syndrome : reported with 5-HT 3 receptor antagonists alone, but particularly with concomitant use of serotonergic drugs. (etiqueta de Palonosetrón, Advertencias y precauciones)

Serotonin syndrome : reported with 5-HT 3 receptor antagonists alone, but particularly with concomitant use of serotonergic drugs. (etiqueta de Palonosetrón, Advertencias y precauciones)

Serotonin syndrome : reported with 5-HT 3 receptor antagonists alone, but particularly with concomitant use of serotonergic drugs. (etiqueta de Palonosetrón, Advertencias y precauciones)

Patients should be monitored for the emergence of serotonin syndrome, especially with concomitant use of POSFREA and other serotonergic drugs. (etiqueta de Palonosetrón, Advertencias y precauciones)

Patients should be monitored for the emergence of serotonin syndrome, especially with concomitant use of POSFREA and other serotonergic drugs. (etiqueta de Palonosetrón, Advertencias y precauciones)

Patients should be monitored for the emergence of serotonin syndrome, especially with concomitant use of POSFREA and other serotonergic drugs. (etiqueta de Palonosetrón, Advertencias y precauciones)

Patients should be monitored for the emergence of serotonin syndrome, especially with concomitant use of POSFREA and other serotonergic drugs. (etiqueta de Palonosetrón, Advertencias y precauciones)

Patients should be monitored for the emergence of serotonin syndrome, especially with concomitant use of POSFREA and other serotonergic drugs. (etiqueta de Palonosetrón, Advertencias y precauciones)

Serotonin syndrome : reported with 5-HT 3 receptor antagonists alone, but particularly with concomitant use of serotonergic drugs. (etiqueta de Palonosetrón, Advertencias y precauciones)

Serotonin syndrome : reported with 5-HT 3 receptor antagonists alone, but particularly with concomitant use of serotonergic drugs. (etiqueta de Palonosetrón, Advertencias y precauciones)

Serotonin syndrome : reported with 5-HT 3 receptor antagonists alone, but particularly with concomitant use of serotonergic drugs. (etiqueta de Palonosetrón, Advertencias y precauciones)

Patients should be monitored for the emergence of serotonin syndrome, especially with concomitant use of POSFREA and other serotonergic drugs. (etiqueta de Palonosetrón, Advertencias y precauciones)

• Serotonin Syndrome : Increased risk when co-administered with other serotonergic agents, but also when taken alone. (etiqueta de Ziprasidona, Advertencias y precauciones)

Serotonin syndrome : reported with 5-HT 3 receptor antagonists alone, but particularly with concomitant use of serotonergic drugs. (etiqueta de Palonosetrón, Advertencias y precauciones)

Serotonergic Drugs The concomitant use of opioids with other drugs that affect the serotonergic neurotransmitter system, such as selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that effect the serotonin neurotransmitter system… (etiqueta de Nalbufina, Interacciones medicamentosas)

Most reports have been associated with concomitant use of serotonergic drugs (e.g., selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), monoamine oxidase inhibitors, mirtazapine, fentanyl, lithium, tramadol, and intravenous methylene blue). (etiqueta de Palonosetrón, Advertencias y precauciones)

The safety and efficacy of combination therapy with phentermine and any other drug products for weight loss including prescribed drugs, over-the-counter preparations, and herbal products, or serotonergic agents such as selective serotonin reuptake inhibitors (e.g., fluoxetine, sertraline, fluvoxamine, paroxetine), have not been established. (etiqueta de Fentermina, Advertencias y precauciones)

Most reports have been associated with concomitant use of serotonergic drugs (e.g., selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), monoamine oxidase inhibitors, mirtazapine, fentanyl, lithium, tramadol, and intravenous methylene blue). (etiqueta de Palonosetrón, Advertencias y precauciones)

Serotonergic Drugs Clinical Impact: The concomitant use of opioids with other drugs that affect the serotonergic neurotransmitter system has resulted in serotonin syndrome [see Adverse Reaction ( 6.2)]. (etiqueta de Oxicodona y paracetamol, Interacciones medicamentosas)

Most reports have been associated with concomitant use of serotonergic drugs (e.g., selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), monoamine oxidase inhibitors, mirtazapine, fentanyl, lithium, tramadol, and intravenous methylene blue). (etiqueta de Palonosetrón, Advertencias y precauciones)